Table 2.

Characteristics of treated patients

Characteristic	Vosaroxin schedule				Total (n = 73)
	Weekly (n = 42)		Twice weekly (n = 31)		No.	%
	No.	%	No.	%
Age, years
Median	65		65		65
Range	21–81		26–85		21–85
Sex
Male	27	64	18	58	45	62
Female	15	36	13	42	28	38
Race or ethnicity
Asian	1	2	1	3	2	3
Black or African American	6	14	3	10	9	12
Hispanic or Latino	4	10	5	16	9	12
White	31	74	22	71	53	73
ECOG performance status
0–1	38	90	30	97	68	93
2	4	10	1	3	5	7
Diagnosis
AML	35	83	27	87	62	85
ALL	4	10	4	13	8	11
MDS transformed to AML	3	7	0	0	3	4
Disease status
Relapsed	7	17	7	23	14	19
Refractorya	34	81	23	74	57	78
Others	1	2	1	3	2	3
No. of prior chemotherapy regimens
0–3	24	57	15	48	39	53
4–9	18	43	16	52	34	47

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ECOG, Eastern Cooperative Oncology Group; MDS, myelodysplastic syndrome.

^aDefined as not achieving complete remission after most recent prior leukemia therapy.